Complete case analysis - Table 1. Baseline characteristics of participants with complete data when outcome is defined by perceived pain at 6-month follow-up. Chronic pain (N = 67) was defined by the presence of pain $(NRS \ge 1)$ and recovery by the absence of pain (N = 29, NRS = 0) at six-month follow up.

Characteristic	Recovered (N = 29)	Chronic pain (N = 67)	P _{FDR} value
Gender: Female (%)	48.2	55.2	0.88
Previous history of LBP: No (%)	28.6	21.2	0.86
BDNF genotype: AA/AG (%)	31.0	38.8	0.86
Cultural diversity: No (%)	53.6	59.1	0.95
L3 map volume (cm ²)	9.6 (3.8)	7.9 (4.0)	0.22
L5 map volume (cm ²)	7.8 (2.6)	7.9 (3.9)	0.96
Log-transformed $N_{80}SEP$ area (μV)	-1.6 (1.3)	-3.2 (1.4)	< 0.001
Log-transformed N_{150} SEP area (μV)	-1.6 (1.2)	-3.0 (1.4)	< 0.001
Age (years) \$	33.9 (11.9)	42.1 (16.4)	0.02
Socioeconomic status (SEIFA score)	1023.7 (51.3)	1021.7 (64.5)	0.96
BDNF serum concentration (pg/mL)	48189.3 (11343.6)	54030.1 (14462.4)	0.22
Log-transformed CRP (pg/mL)	14.2 (1.3)	14.8 (1.4)	0.22
TNF (pg/mL)	6.88 (1.8)	7.8 (2.0)	0.16
PCS score \$	6.0 (7.1)	12.5 (10.9)	< 0.01
DASS-21 score \$	8.4 (7.5)	23.8 (21.0)	< 0.001
PSEQ score \$	52.5 (8.5)	44.8 (12.7)	< 0.01
Local sensitivity (kPa)	943.0 (367.1)	835.0 (361.3)	0.31
Distal sensitivity (kPa)	641.3 (269.0)	638.5 (216.6)	0.96

Variable means were compared between non-recovered and recovered low back pain participants using t tests (continuous variable) or X^2 tests (categorical variables). Y^2 Welch's t test was performed.

Statistically significant values are in bold font

Continuous data described as pooled mean \pm pooled SD. Categorical data described as percent.

AA/AG - G allele encodes Val, A allele encodes Met; BDNF - brain derived neurotrophic factor; CRP - C-reactive protein; DASS - depression, anxiety, stress subscale; FDR - false discover rate; LBP - low back pain; PCS - pain catastrophizing scale; PSEQ - pain self-efficacy questionnaire; TNF- α - tumor necrosis factor.

Complete case analysis - Table 2. Baseline characteristics of participants with complete data when outcome is defined by disability. Chronic disability (N = 35) was defined by RMDQ \geq 3 and recovery by RMDQ score of \leq 2 (N = 61) at six-month follow up.

Characteristic	Recovered (N = 61)	Chronic disability (N = 35)	P _{FDR} value	
Gender: Female (%)	55.7	49.0	0.71	
Previous history of LBP: No (%)	26.7	17.6	0.65	
BDNF genotype: AA/AG (%)	41.0	28.6	0.52	
Cultural diversity: No (%)	55.0	61.8	0.71	
L3 map volume (cm ²)	9.3 (4.0)	6.6 (3.3)	0.03	
L5 map volume (cm ²)	8.3 (3.3)	6.9 (3.9)	0.28	
Log-transformed N_{80} SEP area (μV)	-2.4 (1.5)	-3.2 (1.5)	0.10	
Log-transformed N_{150} SEP area (μV)	-2.4 (1.5)	-2.85 (1.47)	0.34	
Age (years) \$	36.6 (13.9)	44.9 (17.0)	0.06	
Socioeconomic status (SEIFA score)	1019.2 (59.6)	1027.8 (62.5)	0.65	
BDNF serum concentration (pg/mL)	50573.7 (13232.0)	55156.8 (14449.8)	0.34	
Log-transformed CRP (pg/mL)	14.4 (1.3)	14.9 (1.4)	0.29	
TNF (pg/mL)	7.40 (2.0)	7.8 (1.9)	0.65	
PCS score \$	8.0 (8.6)	15.0 (11.6)	0.01	
DASS-21 score \$	14.0 (16.0)	28.2 (21.6)	0.01	
PSEQ score \$	50.6 (9.6)	40.9 (13.6)	< 0.01	
Local sensitivity (kPa)	854.9 (352.5)	887.8 (388.2)	0.71	
Distal sensitivity (kPa)	641.4 (254.2)	635.9 (193.4)	0.91	

Variable means were compared between non-recovered and recovered low back pain participants using t tests (continuous variable) or X^2 tests (categorical variables).


Statistically significant values are in bold font

Continuous data described as mean \pm SD. Categorical data described as percent.


AA/AG - G allele encodes Val, A allele encodes Met; BDNF – brain derived neurotrophic factor; CRP - C-reactive protein; DASS – depression, anxiety, stress subscale; FDR – false discover rate; LBP – low back pain; PCS – pain catastrophizing scale; PSEQ – pain self-efficacy questionnaire; TNF-α - tumor necrosis factor.

^{\$} Welch's t test was performed.


Complete case analysis - Figure 1. Violin plots displaying the log-transformed distribution of baseline primary (N_{80}) and secondary (N_{150}) sensory evoked potential area under the curve mean amplitude (μV) values, divided into those who recovered from their episode of acute LBP and those who developed **chronic pain** ($NRS \ge 1$) at 6-months follow up. Boxplots represent median (horizontal line), 25th and 75th percentiles (box), and 10^{th} and 90th percentiles (lines outside the box). Raw values were log-transformed prior to analysis.




Complete case analysis - Figure 2. Violin plots displaying the log-transformed distribution of baseline primary (N_{80}) and secondary (N_{150}) sensory evoked potential area under the curve mean amplitude (μV) values, divided into those who recovered from their episode of acute LBP and those who developed **chronic disability** (RMDQ \geq 3) at 6-months follow up. Boxplots represent median (horizontal line), 25th and 75th percentiles (box), and 10^{th} and 90th percentiles (lines outside the box). Raw values were log-transformed prior to analysis.



Complete case analysis - Figure 3. Violin plots displaying the distribution of baseline map volume (cm²) from the L3 and L5 electromyographic recording sites, divided into those who recovered from their episode of acute LBP and those who developed **chronic** pain (NRS ≥ 1) at six-month follow-up. Boxplots represent median (horizontal line), 25th and 75th percentiles (box), and 10th and 90th percentiles (lines outside the box).



Complete case analysis - Figure 4. Violin plots displaying the distribution of baseline map volume (cm 2) from the L3 and L5 electromyographic recording sites, divided into those who recovered from their episode of acute LBP and those who developed chronic disability (RMDQ \geq 3) at six-month follow-up. Boxplots represent median (horizontal line), 25th and 75th percentiles (box), and 10^{th} and 90th percentiles (lines outside the box).



Complete case analysis - Table 3. Adjusted and unadjusted linear regression models, including only complete cases, to test the effects of baseline sensorimotor cortex activity on pain intensity and RMDQ score at six-month follow-up.

Outcome	Model	Exposure	B (95% CI)	$P_{ m FDR}$
Pain Intensity	Unadjusted	Log-transformed N ₈₀ SEP area	-0.58 (-0.85, -0.31)	< 0.001
		Log-transformed N ₁₅₀ SEP area	-0.54 (-0.83, -0.25)	< 0.01
		L3 map volume	-0.18 (-0.30, -0.06)	0.01
		L5 map volume	-0.06 (-0.20, 0.08)	0.41
	Adjusted ¹	Log-transformed $N_{80}SEP$ area	-0.14 (-0.55, 0.26)	0.63
		Log-transformed $N_{150}SEP$ area	-0.23 (-0.63, 0.17)	0.49
		L3 map volume	-0.16 (-0.35, 0.02)	0.32
		L5 map volume	-0.03 (-0.22, 0.17)	0.77
RMDQ score	Unadjusted	Log-transformed $N_{80}SEP$ area	-0.42 (-1.02 ,0.17)	0.36
		Log-transformed N ₁₅₀ SEP area	-0.33 (-0.96 ,0.30)	0.41
		L3 map volume	-0.18 (-0.45, 0.09)	0.36
		L5 map volume	0.06 (-0.24 ,0.37)	0.69
	Adjusted ¹	Log-transformed N ₈₀ SEP area	-0.42 (-1.28, 0.45)	0.44
		Log-transformed N ₁₅₀ SEP area	-0.62 (-1.47, 0.23)	0.29
		L3 map volume	-0.46 (-0.88, -0.04)	0.13
		L5 map volume	-0.11 (-0.56, 0.35)	0.63

¹ Adjusted for predisposing factors, blood biomarkers, psychological variables and sensitisation. Statistically significant values are in bold font

B – unstandardized beta coefficient, CI – confidence interval, FDR – false discovery rate, SEP – somatosensory evoked potential

Complete case analysis - Table 4. Adjusted and unadjusted logistic regression models, including only complete cases, to test the effects of baseline sensorimotor activity on chronic pain and chronic disability at six-month follow-up.

Outcome	Model	Exposure	OR (95% CI)	$P_{ m FDR}$	E-Value	E CI
Chronic pain &	Unadjusted	Log-transformed N ₈₀ SEP area	2.08 (1.52, 3.03)	< 0.001	2.24	1.76
		Log-transformed N ₁₅₀ SEP area	2.04 (1.45, 2.94)	< 0.001	2.21	1.70
		L3 map volume n.b.	1.11 (0.98, 1.28)	0.15	1.29	1.00
		L5 map volume	0.99 (0.85, 1.15)	0.91	1.08	1.00
	Adjusted ¹	Log-transformed N ₈₀ SEP area	3.45 (1.30, 14.29)	0.08	3.12	1.54
		Log-transformed N ₁₅₀ SEP area	7.14 (2.04, 100.00)	0.07	4.79	2.21
		L3 map volume n.b.	1.16 (0.93, 1.49)	0.23	1.37	1.00
		L5 map volume	1.12 (0.67, 2.00)	0.61	1.31	1.00
Chronic disability #	Unadjusted	Log-transformed N ₈₀ SEP area	1.37 (1.03, 1.85)	0.07	1.62	1.14
		Log-transformed N ₁₅₀ SEP area	1.22 (0.92, 1.67)	0.18	1.44	1.00
		L3 map volume n.b.	1.25 (1.06, 1.52)	0.04	1.48	1.21
		L5 map volume	1.14 (0.98, 1.35)	0.15	1.33	1.00
	Adjusted ¹	Log-transformed N ₈₀ SEP area	2.00 (0.99, 5.00)	0.22	2.18	1.00
		Log-transformed N ₁₅₀ SEP area	1.69 (0.93, 3.45)	0.22	1.93	1.00
		L3 map volume n.b.	1.16 (0.93, 1.56)	0.23	1.37	1.00
		L5 map volume	1.45 (0.93, 3.70)	0.23	1.70	1.00

[&]amp; Chronic pain in this logistic model was defined as NRS score ≥ 1 at 6-month follow up.

CI – confidence interval; DASS – depression, anxiety, stress subscale; FDR – false discovery rate; OR – odds ratio; PPT – pressure pain threshold; SEP – somatosensory evoked potential; TNF – tumor necrosis factor.

[#] Chronic disability in this logistic model was defined as RMDQ score ≥ 3 at 6-month follow up.

¹Adjusted for predisposing factors, blood biomarkers, psychological variables and sensitisation.

n.b. L3 map volume logistic regression models were not adequately powered to detect a meaningful effect. Therefore, we controlled for age, DASS, TNF-α and local PPT, a single variable from each confounder category. Despite this, no meaningful effects were observed, therefore this is unlikely to impact study conclusions. Statistically significant values are in bold font